Tianeptine dose: what do studies and labels say?

What the labels give
LabelWhoDaily dose
Singapore HSA, Stablon1Recommended dosageOne 12.5 mg tablet three times a day (morning, midday and evening), at the beginning of the main meals
Singapore HSA, Stablon1Over 70, or renal insufficiency2 tablets a day
Polish SmPC, Atinepte2Recommended dosage (12.5 mg tablet)One tablet three times a day (morning, midday and evening), before the main meals
Polish SmPC, Atinepte2Frail, lean elderly patients under 55 kgTwo tablets
Polish SmPC, Atinepte2Severe renal impairment, creatinine clearance below 19 ml/minTwo tablets

The Singapore and Polish labels for tianeptine sodium give one 12.5 mg tablet three times a day, and two tablets a day for some groups, among them people with renal insufficiency or severe renal impairment.12

What the labels give

The table is set at the top of the page

The labels differ on age: the Polish SmPC says no age-based dose adjustment is needed apart from frail, lean elderly patients under 55 kg, the Singapore label restricts subjects aged over 70 years to 2 tablets a day, and a 2024 review gives 25 mg/day for the elderly.213 The FDA states that tianeptine is not approved in the US for any medical use, and a DailyMed search found no US label.4

What the trials used

TrialDose and schedulePeopleLength
Costa e Silva and colleagues, 1997, major depression or bipolar disorder (depressed), against placebo525-50 mg/day, mean 37.5 mg/day126 depressed outpatients42 days after a 1-week placebo run-in
Kauer-Sant'Anna and colleagues, 2019, bipolar depression, adjunctive, against placebo637.5 mg/day161 participants, 69 randomised (36 tianeptine, 33 placebo)Eight weeks open-label, then a 24-week double-blind phase
NCT04249596, started 2020, treatment-resistant depression, open-label, stopped early7Tianeptine sodium 12.5 mg three times daily at 9am, 1pm and 5pm38 participants (target 75)8 weeks
NCT05686408 (UPLIFT), started 2023, major depressive disorder, against placebo, completed8TNX-601 ER (tianeptine) 39.4 mg extended-release tablet once daily, or a placebo tablet once daily132 participants (64 TNX-601 ER, 68 placebo)6 weeks
NCT06012552 (COVMENT), started 2023, Covid fog symptoms after COVID-19, against placebo, still recruiting9Oral tianeptine 3x 12.5 mg per day (under 70) or 2x 12.5 mg per day (over 70), with group psychotherapy and neurological rehabilitation in both arms140 participants (estimated)16 weeks
NCT01309776 (CAMPION), started 2011, reported by Yoo and colleagues, 2015, major depressive disorder, open-label, against escitalopram 5 mg/day in the first week, then 10 mg/day in the second1025 mg/day once daily in week 1, then 37.5 mg/day twice daily in week 2164 participants12 weeks

Searches returned no completed pain or anxiety trial with results, only registry entries without results.

Half-life and older people

A 2024 review reports that a single 12.5 mg oral dose of the sodium salt in 12 healthy volunteers (6 men and 6 women) peaked at 0.94 ± 0.47 h.3 A 1988 pharmacokinetic paper by Royer and colleagues reports a short mean elimination half-life of 2.5 ± 1.1 h.11 The same paper says the half-life is prolonged by 1 hour in renal failure and in the elderly, suggesting a limit of two tablets per day.11 The Polish SmPC gives an elimination half-life of three hours.2

Stopping tianeptine

The Singapore label says abrupt discontinuation is to be avoided, and both it and the Polish SmPC give a gradual dose reduction over 7 to 14 days to reduce the risk of withdrawal reactions.12 A 2026 systematic review of tianeptine misuse by Anand and colleagues found that, among its 52 individual cases, 26/52 (50%) presented with withdrawal.12

Doses above the labelled ones

The FDA says case reports in the medical literature describe US consumers taking daily doses on the order of 1.3 to 250-fold (50 mg to 10,000 mg) the daily dose typically recommended in labeled foreign drug products.4 The FDA warns consumers not to purchase or use any product with tianeptine, and says it continues to receive severe adverse event reports after use of Neptune's Fix products, including seizures, loss of consciousness and death.4 The Polish SmPC says not to give doses larger than recommended.2

Storage and mixing

The Polish SmPC gives a shelf life of two years and says not to store the tablets above 25°C.2 The French ANSM SmPC for Stablon gives a shelf life of 36 mois (months), with no special storage precautions in climatic zones I and II and storage not above 30°C in climatic zones III and IV.13 Searches of labels, regulator pages, DailyMed, PubMed and trial registries found no tianeptine solution, oral liquid or injectable with a mg/mL concentration and no instruction for mixing a powder with water, so there is no concentration to convert to a syringe mark.

Frequently asked questions

Is tianeptine sulfate dosed differently?

Searches of PubMed and trial registries for tianeptine sulfate, which were not done in depth, returned only sodium salt products and found no labelled sulfate product.

References

  1. Singapore HSA. STABLON TABLET 12.5 MG [SIN11182P]. ndf.gov.sg
  2. Polpharma SmPC (Poland). CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. polpharma.pl
  3. PMC. Classics in Chemical Neuroscience: Tianeptine. 2024. pmc.ncbi.nlm.nih.gov
  4. US FDA. FDA warns consumers not to purchase or use any tianeptine product due. fda.gov
  5. PubMed. Placebo-controlled study of tianeptine in major depressive episodes. 1997. pubmed.ncbi.nlm.nih.gov
  6. PubMed. Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. 2019. pubmed.ncbi.nlm.nih.gov
  7. ClinicalTrials.gov. NCT04249596: Tianeptine for Treatment Resistant Depression. 2026. clinicaltrials.gov
  8. ClinicalTrials.gov. NCT05686408: Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD). 2025. clinicaltrials.gov
  9. ClinicalTrials.gov. NCT06012552: Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19. 2027. clinicaltrials.gov
  10. ClinicalTrials.gov. NCT01309776: Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder. 2012. clinicaltrials.gov
  11. PubMed. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors. 1988. pubmed.ncbi.nlm.nih.gov
  12. PubMed. Tianeptine misuse and addiction: A systematic review of withdrawal, toxicity, and clinical management. 2026. pubmed.ncbi.nlm.nih.gov
  13. ANSM France. R�sum� des Caract�ristiques du Produit. agence-prd.ansm.sante.fr